MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics (MLTX) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | C+ (2.5) | C- (1.9) | C- (2.0) | D+ (1.8) | C+ (2.6) | C (2.2) |
| 2026-11-06 | C+ (2.5) | D+ (1.8) | C- (2.1) | D+ (1.6) | C+ (2.7) | C- (2.1) |
| 2026-10-30 | C+ (2.5) | D+ (1.8) | C- (2.1) | D+ (1.8) | C+ (2.7) | C (2.2) |
| 2026-10-23 | C+ (2.5) | D+ (1.8) | C- (2.1) | C- (1.9) | C+ (2.6) | C (2.2) |
| 2026-10-16 | C+ (2.5) | D+ (1.8) | C- (2.1) | D+ (1.6) | C+ (2.6) | C- (2.1) |